centered

Olympic Therapeutics was formed by specialists to develop a new class of Antifungal Medications for the treatment of resistant Fungal Infections.

Fungal Infections

Over 300 Mln. peoples worldwide infected.

High Risk

25 Mln. are at high risk of dying or decline.

Olympic Therapeutics

develops a new class of Antifungal Medications

Olympic Therapeutics AG

overview

ILO

Initial License Offering

Fungal Diseases

adv

Globally, over 300 million people are afflicted with a serious fungal infection and 25 milllion are at high risk of dying or losing their sight.

adv

For years, we have been researching the treatment of complicated fungal diseases and have successfully started to develop appropriate drugs.

adv

In order to bring our previous research results and the associated drugs to market, Olympic Therapeutics AG was founded by researchers and scientists.

40%

revenue
pot

ILO Price

€2,000
Exchanges View
Buy Now

green sheet

the numbers

6,000

ILO Units in Initial Issue

€12,000,000

Total to be raised

6,000

ILO Units in Total Issue

  • projections
  • milestones

2018

Q2

2018

Q3

2018

Q4

2019

Q1

2019

Q2

2018

Q2

2018

Q3
zmeyka

2018

Q4

2019

Q1

2019

Q2
chartB

Proposed Date of Initial ILO

Currency

Current Gross Revenues

Initial Price per Unit

Contract Maturity Terms

line

Year 1

€12,000,000
Revenue

Year 2

€14,000,000
Revenue

Year 3

€216,000,000
Revenue

meet the team

Olympic Therapeutics AG Team

Hans Werner Balz

CEO

Read More
closeq
Hans Werner Balz

CEO

Hans Werner Balz is MBA and has many years in experience in the pharma business as certified clinical consultant and as Director of a global acting pharma company.

Dr. Richard Honour

Chief Scientific Director(CSD, USA Division)

Read More
closeq
Dr. Richard Honour

Chief Scientific Director(CSD, USA Division)

Dr Honour is a PhD and responsible for Research and Product Development. He has decades of experience in the industry at senior executive levels and various board of director positions. He is known world wide for his expertise in bacteriophages and infectious diseases.

Dr. Warren Wheeler

Chief Product Development and Business Director(CPDBD, USA Division)

Read More
closeq
Dr. Warren Wheeler

Chief Product Development and Business Director(CPDBD, USA Division)

Dr Wheeler is an MD, MBA, and has decades of global experience in the development of successful biopharmaceuticals. In addition, he has held significant senior level executive positions in the industry. He currently serves on the Board of Directors of three companies.

Raik Heinzelmann

President of the Supervisory Board

Read More
closeq
Raik Heinzelmann

President of the Supervisory Board

Mr. Heinzelmann has long year is a trained banker and has many years of experience as CFO of a bank and is CEO of a exchange listed finance company. Mr. Heinzelmann is also in the supervisory board of a German software company.

Nicolai Colshorn

Member of Supervisory Board

Read More
closeq
Nicolai Colshorn

Member of Supervisory Board

Mr. Colshorn has a diploma from the University of Stuttgart and many years of experience as a supervisory board member and director of various companies.

read more

Documents

Olympic Therapeutics Overview

icon The Problem | Markets | Products

Download

contact

More information about Olympic Therapeutics AG